Articles tagged "Antilymphocyte antibodies"

2019 American Transplant Congress
Comparison of Long-Term Outcomes between Alemtuzumab and Rabbit Anti-Thymocyte Globulin for Acute Kidney Allograft Rejection
M. van der Zwan, M. C. Clahsen-van Groningen, D. L. Roelen, M. W. van den Hoogen, M. Van Agteren, J. I. Roodnat, C. C. Baan, D. A. Hesselink
Erasmus MC, Rotterdam, Netherlands
*Purpose: T cell-depleting antibody therapy with rabbit anti-thymocyte globulin (rATG) is the treatment of choice for glucocorticoid-resistant, recurrent and/or severe acute kidney allograft rejection (AR).…
2019 American Transplant Congress
Case Series: Anti-Thymocyte Globulin as a Treatment for Steroid-Refractory Severe Acute Hepatitis in Children
A. L. Peters, A. Miethke, K. Campbell
Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
*Purpose: Pediatric severe acute hepatitis (SAH), when not attributed to acetaminophen toxicity, is commonly hypothesized to be caused by a non-typeable viral infection and/or immune…
2019 American Transplant Congress
ABMR In Low-single Dose Thymoglobulin Induction Protocol In Renal Transplant Recepients From A Tertiary Care Centre In A Developing Country
R. Parthasarathy¹, M. Mohammed¹, P. Koshy², I. Pradeep², M. Mathew¹, G. Abraham¹
¹Nephrology, Madras Medical Mission, Chennai, India, ²Pathology, Madras Medical Mission, Chennai, India
*Purpose: Fool proof induction therapy in low sensitized patients is still elusive. There is a thin line between over immunosuppression and infection . Conventional rabbit…
2019 American Transplant Congress
Retrospective Nested Case Control Study of the Impact of Immunosuppression on Post Transplant Malignancy among Adult Heart Transplant Patients
S. Crow, R. J. Bubik, S. S. Kushwaha, K. C. Mara, R. A. Dierkhising, N. L. Pereira
Mayo Clinic, Rochester, MN
*Purpose: Post-transplant malignancy is diagnosed in approximately 18% of heart transplant (HTx) recipients and is a leading long-term cause of death among these patients. The…
2019 American Transplant Congress
Allogenic Islets Cure Diabetes Following Transplantation in Omental Pouch in a Non-Human Primate Model
J. Lei¹, H. Deng¹, K. Lee¹, C. Peters¹, G. Rickert¹, R. Ivy¹, M. Coronel², E. Yolcu³, H. Shirwan⁴, A. García⁵, J. Markmann¹
¹Surgery, Massachusetts General Hospital, Boston, MA, ²Surgery, Georgia Institute of Technology, Atlanta, GA, ³Institute for Cellular Therapeutics, University of Louisville School of Medicine, louisville, KY, ⁴Department of Microbiology and Immunology, University of Louisville School of Medicine, louisville, KY, ⁵School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA
*Purpose: In the current standard clinical transplant approach, islet cells are administered intravenously into the portal system where they lodge in the liver. This approach…
2019 American Transplant Congress
To Each Their Own: Center-Level Variation in Tailoring Induction Immunosuppression to Kidney Transplant Recipients
S. Bae, A. Massie, J. Garonzik Wang, M. McAdams DeMarco, J. Coresh, D. Segev
Johns Hopkins University, Baltimore, MD
*Purpose: Ideally, induction immunosuppression should be selected in a personalized manner. However, there is little knowledge of what clinical factors are considered in this process…
2019 American Transplant Congress
Low Dose Anti-Thymocyte Globulin is Enough to Prevent Acute Cellular Rejection in Kidney Transplant
P. W. Baron¹, J. Weissman², F. Fazeli³, C. Zuppan⁴, R. Villicana³, P. Wai¹, L. Beeson⁵, M. De Vera¹
¹Surgery/Transplantation Institute, Loma Linda University Health, Loma Linda, CA, ²Pharmacy, Loma Linda University Health, Loma Linda, CA, ³Transplantation Institute, Loma Linda University Health, Loma Linda, CA, ⁴Pathology, Loma Linda University Health, Loma Linda, CA, ⁵Center for Nutrition, Healthy Lifestyle and Disease Prevention/School of Public Health, Loma Linda University Health, Loma Linda, CA
*Purpose: Rabbit anti-thymocyte globulin (rATG) cumulative dose needed to effectively and safely prevent acute cellular rejection is unknown. This study compares the efficacy of total…
2019 American Transplant Congress
Alemtuzumab versus Antithymocyte Globulin Induction Immunosuppression in Highly Sensitized Kidney Transplant Recipients
A. Brueckner¹, E. Yanqui¹, C. Truong¹, R. Baliga², L. Bowman¹
¹Tampa General Hospital, Tampa, FL, ²Florida Kidney Physicians, Tampa, FL
*Purpose: Lymphocyte depleting agents such as rabbit anti-thymocyte globulin (rATG) and alemtuzumab are used for induction in highly sensitized (PRA ≥30%) kidney transplant recipients (KTRs).…
2018 American Transplant Congress
Comparison of Induction and Maintenance Immunosuppression Regimens in Intestinal and Multivisceral Transplantation: An Analysis of the UNOS Registry
S. Nagai,¹ M. Rizzari,¹ Y. Muszkat,² K. Collins,¹ A. Yoshida,¹ S-.M. Jafri,² M. Abouljoud.¹
¹Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI; ²Gastroenterology, Henry Ford Hospital, Detroit, MI.
Aim: Induction and maintenance immunosuppression regimens in intestinal transplant widely vary among centers. The aim of this study was to investigate an association between immunosuppression…
2018 American Transplant Congress
Thymoglobulin Induction Decreases Risk of Death in HLA-Sensitized Kidney Recipients
C. Loheac, O. Aubert, M. Assayag, D. Viglietti, C. Lefaucheur, A. Loupy.
Paris Translational Research Center for Organ Transplantation, Paris, France.
Anti-thymocyte globulin (ATG) is currently the preferential induction treatment in kidney recipients at high risk for allograft rejection. However, no study has evaluated the benefits…